Secundum Atrial Septal Defects and Methylenetetrahydrofolate Reductase C677T Polymorphism: A Special Category of ASDs?

Marco Zuin,Gianluca Rigatelli

DOI: https://doi.org/10.1016/j.ijcard.2016.08.212

IF: 4.039

2016-01-01

International Journal of Cardiology

Abstract:Atrial septal defects (ADSs) are one of the most common types of congenital heart disease (CHD) in adulthood [ [1] Rigatelli G. Cardaioli P. Hijazi Z.M. Contemporary clinical management of atrial septal defects in the adult. Expert. Rev. Cardiovasc.Ther. 2007; 5: 1135-1146 Crossref PubMed Scopus (20) Google Scholar ]. The formation of the atrial septum is a complex process which starts during morphogenesis and ends with the birth. However, in about 4 of 100,000 new born, an error on this development process will result in a defect of the wall separating the two atria [ [2] Lindsey J.B. Hillis L.D. Clinical update: atrial septal defect in adults. Lancet. 2007; 369: 1244-1246 Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar ]. Methylenetetrahydrofolate reductase (MTHFR) is a fundamental enzyme involved in the metabolism of folate. In particular, is able to covert 5,10-methylenetetrahydrofolateto 5-methylenetetrahydrofolate, converting homocysteine to methionine. Several studies have already associated the association between MTHFR C677T polymorphism with congenital heart disease (CHD). In general, despite have been well assessed that mutations in the genes involved in the folate pathway had an important role in the etiology of birth defects, studies regarding MTHFR C677T polymorphism in relation to CHDs have yielded conflicting conclusions. Moreover, despite MTHFR mutations have also been related with ASDs, only very few studies have analyzed this relationship. Current guidelines on ASDs not take into account these polymorphisms in the management of ASD patients. As final result, clinicians are often doubters about the best medical treatment and follow-up to perform in these patients. The relationship between CHD, folate and hyperhomocysteinemia (Hyper-HCY) could be explained by a mutation in the methylenetetrahydrofolatereductase (MTHFR) gene. In particular, a missense mutation, more precisely a cytosine (C) to thymine (T) substitution at base 677 that cause a replacement of valine for alanine at position 222 of the protein, induces a thermolabile variant of MTHFR with reduced enzymatic action. The final result is a higher plasma level of homocysteine (Hcy), especially in those patients with low-folate levels. Kapusta et al. reported for the first time that maternal Hyper-HCY was correlated with an increased risk of CHDs [ [3] Kapusta L. et al. Congenital heart defects and maternal derangement of homocysteine metabolism. J. Pediatr. 1999; 135: 773-774 Abstract Full Text Full Text PDF PubMed Scopus (124) Google Scholar ]. Zhu et al. have demonstrated that careers of TT genotype and T allele had a higher risk to develop ASDs [ [4] Zhu W.L. Li Y. Yan L. Dao J. Li S. Maternal and offspring MTHFR gene C677T polymorphism as predictors of congenital atrial septal defect and patent ductusarteriosus. Mol. Hum. Reprod. 2006; 12: 51-54 Crossref PubMed Scopus (47) Google Scholar ]. In particular, in their studies they demonstrated that the odds ratio (OR) for ASD in patients with TT genotype was 4.08 (95% confidence interval 1.28–13.2) compared with those with CT genotype [ [4] Zhu W.L. Li Y. Yan L. Dao J. Li S. Maternal and offspring MTHFR gene C677T polymorphism as predictors of congenital atrial septal defect and patent ductusarteriosus. Mol. Hum. Reprod. 2006; 12: 51-54 Crossref PubMed Scopus (47) Google Scholar ]. Similarly, Elsayed et al. reported that maternal MTHFR C677T could be considered as a maternal risk factor for ASDs, especially in children with Down's syndrome (DS) [ [5] Elsayed G.M. Elsayed S.M. Ezz-Elarab S.S. Maternal MTHFR C677T genotype and septal defects in offspring with down syndrome: a pilot study. Egypt. J. Med. Hum. Genet. 2013; 15: 39-44 Abstract Full Text Full Text PDF Scopus (11) Google Scholar ]. Currently, data about management of ASDs in patients with H-Hcys and MTHFR gene polymorphism, with or without previous cardiovascular (CV) events, are lacking. Patients with ASDs are often clinically asymptomatic and the CHD is usually detected incidentally. Conversely, the few symptomatic patients report shortness of breath and fatigue, especially during exercise. Moreover, the age at which symptoms appear is highly variable and is not only related to the size of the shunt but also to others comorbidities, especially those affecting the CV system. Both MTHFR polymorphism and H-Hcys are per se cardiovascular risk factors in these patients. Indeed, it has already been reported in several studies that MTHFR C677T genotype is a risk factor for CV events. In fact, it has been suggested that lowering homocysteine could be an effective preventive treatment for prevention of CV events [ [6] Rodriguez C.J. Homma S. Hypercoagulable states in patients with patent foramen ovale. Curr. Hematol. Rep. 2003; 2: 435-441 PubMed Google Scholar ]. ASDs are also related with stroke, arrhythmia, paradoxical embolism and VTE. In this regard, also MTHFR polymorphism has been described as a congenital risk factor for venous thromboembolism (VTE), paradoxical embolism, and stroke [ [7] Den Heijer M. Lewington S. Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J. Thromb. Haemost. 2005; 2: 292-299 Crossref Scopus (365) Google Scholar ]. Current recommendation suggests that all types of ASDs with right heart enlargement should be considered for closure, independent of age, once the diagnosis is confirmed. Catheter-based closure is preferable in patients with secundum ASD and suitable anatomy. In particular, anatomical inclusion criteria include at least 5-mm rims of tissue on transesophageal echocardiography (TTE), no associated cardiac anomalies, such as partial anomalous pulmonary venous drainage and defect size less than 36–38 mm [ [1] Rigatelli G. Cardaioli P. Hijazi Z.M. Contemporary clinical management of atrial septal defects in the adult. Expert. Rev. Cardiovasc.Ther. 2007; 5: 1135-1146 Crossref PubMed Scopus (20) Google Scholar ]. Given that secondary ostium secundum is the more frequent abnormality, percutaneous closure is the first line therapy. Indeed, it minimizes hospital stay, avoids surgical wounds, and offers the same benefits as surgery. In general, successful closure can be obtained in over 95% of patients, although small residual shunts, which are not hemodynamically significant, may be observed in the immediate post-closure echocardiographic study but will usually close within 1 year of the procedure [ [8] Hein R. Buscheck F. Fischer E. et al. Atrial and ventricular septal defects can safely be closed by percutaneous intervention. J. Interv. Cardiol. 2005; 18: 515-522 Crossref PubMed Scopus (29) Google Scholar ].